Health & Wellness Glofitamab Treatment for DLBCL Shows Cost Savings Over Epcoritamab in US Healthcare Aug 8, 2025 An economic model reveals glofitamab offers DLBCL patient cost savings versus epcoritamab, despite higher adverse event and treatment administration costs.
